TerSera Therapeutics is a privately held biopharmaceutical company based in Deerfield, Illinois, focused on acquiring, developing, and commercializing specialty medicines in oncology, rare disease, and non-opioid pain. Launched in 2016 with backing from private equity firm GTCR, TerSera builds its portfolio through targeted acquisitions of approved and late-stage assets, including ZOLADEX, XERMELO, PRIALT, and VARUBI, with a stated mission of building 'the new cornerstones of care' for patients with limited treatment options.
Tim McAdam is a General Partner at TCV (Technology Crossover Ventures), one of the world's leading growth equity firms, where he has focused on enterprise software, security, and tech-enabled services since joining in 2010. With a career in venture and growth investing that stretches back to the early 1990s at TA Associates, GTCR, and Trinity Ventures, McAdam has backed category-defining companies including GitLab, Splunk, Avalara, Rapid7, Alarm.com, OneTrust, and Vectra. An unlikely archaeology major from Dartmouth turned perennial enterprise investor, he combines a Stanford MBA pedigree with a nose for operational software that sticks.